David Lebowitz
Stock Analyst at Citigroup
(2.33)
# 1,388
Out of 4,479 analysts
70
Total ratings
43.55%
Success rate
-2.17%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $38 → $64 | $33.68 | +90.02% | 3 | Jun 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $18 → $26 | $30.39 | -14.45% | 2 | May 21, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $31 → $29 | $22.15 | +30.93% | 3 | May 10, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $45 → $44 | $10.60 | +315.09% | 4 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $65 → $76 | $110.36 | -31.13% | 5 | May 3, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $39 → $37 | $20.33 | +82.00% | 7 | May 2, 2024 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | $382 | $271.67 | +40.61% | 1 | Mar 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $11 → $13 | $8.24 | +57.77% | 2 | Feb 26, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $46 | $24.91 | +84.66% | 2 | Feb 23, 2024 | |
| INCY Incyte | Maintains: Buy | $82 → $81 | $59.02 | +37.24% | 2 | Feb 14, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $182 | $136.27 | +33.56% | 9 | Feb 8, 2024 | |
| EXEL Exelixis | Initiates: Buy | $31 | $22.15 | +39.95% | 1 | Dec 15, 2023 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $36 → $60 | $45.14 | +32.92% | 8 | Jul 31, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $103 → $96 | $82.22 | +16.76% | 3 | Jun 30, 2023 | |
| IMRX Immuneering | Maintains: Equal-Weight | $18 → $12 | $1.09 | +1,000.92% | 2 | Jul 15, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $170 → $164 | $247.61 | -33.77% | 6 | Jul 15, 2022 | |
| ARQT Arcutis Biotherapeutics | Maintains: Overweight | $36 → $39 | $9.30 | +319.35% | 6 | Jun 7, 2022 | |
| SNDX Syndax Pharmaceuticals | Maintains: Equal-Weight | n/a | $20.66 | - | 1 | Oct 12, 2021 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | n/a | $0.80 | - | 1 | Oct 12, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $6.22 | - | 2 | Oct 12, 2021 |
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Buy
Price Target: $38 → $64
Current: $33.68
Upside: +90.02%
PTC Therapeutics
May 21, 2024
Maintains: Sell
Price Target: $18 → $26
Current: $30.39
Upside: -14.45%
Intellia Therapeutics
May 10, 2024
Maintains: Neutral
Price Target: $31 → $29
Current: $22.15
Upside: +30.93%
Pliant Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $45 → $44
Current: $10.60
Upside: +315.09%
Blueprint Medicines
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $110.36
Upside: -31.13%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $20.33
Upside: +82.00%
Madrigal Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $271.67
Upside: +40.61%
Cogent Biosciences
Feb 26, 2024
Maintains: Buy
Price Target: $11 → $13
Current: $8.24
Upside: +57.77%
BridgeBio Pharma
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $24.91
Upside: +84.66%
Incyte
Feb 14, 2024
Maintains: Buy
Price Target: $82 → $81
Current: $59.02
Upside: +37.24%
Ascendis Pharma
Feb 8, 2024
Maintains: Buy
Price Target: $146 → $182
Current: $136.27
Upside: +33.56%
Exelixis
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $22.15
Upside: +39.95%
Ionis Pharmaceuticals
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $45.14
Upside: +32.92%
BioMarin Pharmaceutical
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $82.22
Upside: +16.76%
Immuneering
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.09
Upside: +1,000.92%
Alnylam Pharmaceuticals
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $247.61
Upside: -33.77%
Arcutis Biotherapeutics
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $9.30
Upside: +319.35%
Syndax Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $20.66
Upside: -
Karyopharm Therapeutics
Oct 12, 2021
Maintains: Overweight
Price Target: n/a
Current: $0.80
Upside: -
Ironwood Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $6.22
Upside: -